المؤلفون: Jørgensen, TS¹ (AUTHOR) tanja.schjoedt.joergensen@regionh.dk, Hansen, RL¹ (AUTHOR), Pouls, B^2,3 (AUTHOR), Van den Bemt, B^2,3 (AUTHOR), Sjöwall, C⁴ (AUTHOR), Kristensen, LE¹ (AUTHOR)

المصدر: Scandinavian Journal of Rheumatology. Jan2025, Vol. 54 Issue 1, p25-32. 8p.

مصطلحات موضوعية: *CERTOLIZUMAB pegol, *PATIENT satisfaction, *PSORIATIC arthritis, *RHEUMATOID arthritis, *DISEASE duration

المؤلفون: Lehmann, Anouk¹ (AUTHOR), Vosbeck, Juerg² (AUTHOR), Kyburz, Diego³ (AUTHOR), Hruz, Petr¹ (AUTHOR), Niess, Jan Hendrik^1,4 (AUTHOR) janhendrik.niess@unibas.ch

المصدر: Case Reports in Gastroenterology. Dec2024, Vol. 19 Issue 1, p22-30. 9p. 3 Illustrations.

مصطلحات موضوعية: *CERTOLIZUMAB pegol, *BIOTHERAPY, *SPONDYLOARTHROPATHIES, *THERAPEUTICS, *DISEASE progression

المؤلفون: Li, Dan¹ (AUTHOR), Zhang, Xinhui¹ (AUTHOR), Tian, Yunfei² (AUTHOR), Zhang, Jing³ (AUTHOR), Zhao, Xiaojuan¹ (AUTHOR), Li, Menghao¹ (AUTHOR), Zhao, Yonghong¹ (AUTHOR), Liu, Xiuju¹ (AUTHOR) 27400068@hebmu.edu.cn

المصدر: International Archives of Allergy & Immunology. Dec2024, p1-18. 18p. 12 Illustrations.

مصطلحات موضوعية: *TUMOR necrosis factors, *CERTOLIZUMAB pegol, *SPONDYLOARTHROPATHIES, *KINASE inhibitors, *RANDOMIZED controlled trials

المؤلفون: Jeong, Yi Deun^1,2 (AUTHOR), Jo, Hyesu^1,3 (AUTHOR), Cho, Hanseul^1,2 (AUTHOR), Jang, Wonwoo^1,2 (AUTHOR), Park, Jaeyu^1,3 (AUTHOR), Lee, Sooji^1,2 (AUTHOR), Lee, Hayeon¹ (AUTHOR), Lee, Kyeongmin^1,3 (AUTHOR), Oh, Jiyeon^1,2 (AUTHOR), Wen, Xuerong⁴ (AUTHOR), Smith, Lee⁵ (AUTHOR), Yon, Dong Keon^1,2,3,6 (AUTHOR) lee.smith@aru.ac.uk

المصدر: International Archives of Allergy & Immunology. Dec2024, p1-15. 15p. 4 Illustrations.

مصطلحات موضوعية: *CERTOLIZUMAB pegol, *TUMOR necrosis factors, *PREGNANT women, *DATABASES, *ODDS ratio

المؤلفون: Barroso-García, Nuria¹ (AUTHOR) nubarroso@hotmail.com, Martín-Varillas, José Luis^2,3 (AUTHOR) hernandezjluis@gmail.com, Ferraz-Amaro, Iván⁴ (AUTHOR) iferrazamaro@hotmail.com, Sánchez-Bilbao, Lara^3,5 (AUTHOR), Martín-Gutiérrez, Adrián^3,5 (AUTHOR), Adán, Alfredo⁶ (AUTHOR), Hernanz-Rodríguez, Inés⁶ (AUTHOR), Beltrán-Catalán, Emma⁷ (AUTHOR), Cordero-Coma, Miguel⁸ (AUTHOR), Díaz-Valle, David⁹ (AUTHOR), Hernández-Garfella, Marisa¹⁰ (AUTHOR), Martínez-Costa, Lucía¹¹ (AUTHOR), Díaz-Llopis, Manuel¹² (AUTHOR), Herreras, José M.¹³ (AUTHOR), Maíz-Alonso, Olga¹⁴ (AUTHOR), Torre-Salaberri, Ignacio¹⁵ (AUTHOR), Atanes-Sandoval, Antonio¹⁶ (AUTHOR), Insúa, Santos¹⁷ (AUTHOR), Almodóvar-González, Raquel¹⁸ (AUTHOR), Fanlo, Patricia¹⁹ (AUTHOR)

المصدر: Journal of Clinical Medicine. Dec2024, Vol. 13 Issue 23, p7388. 12p.

مصطلحات موضوعية: *BEHCET'S disease, *CERTOLIZUMAB pegol, *MACULAR edema, *IMMUNOSUPPRESSIVE agents, *DEMOGRAPHIC characteristics

المؤلفون: Sahuquillo‐Torralba, Antonio¹ (AUTHOR), Mansilla‐Polo, Miguel¹ (AUTHOR) miguel_yecla96@hotmail.com, Pujol‐Marco, Conrad¹ (AUTHOR), Llamas‐Velasco, Mar² (AUTHOR), Rull, Eva V.³ (AUTHOR), Ruiz Villaverde, Ricardo⁴ (AUTHOR), Ferran, Marta⁵ (AUTHOR), Pitarch, Gerard⁶ (AUTHOR), Lopez, Anna³ (AUTHOR), Beltran, Emma⁷ (AUTHOR), Urruticoechea‐Arana, Ana⁸ (AUTHOR), Riera‐Monroig, Josep⁹ (AUTHOR), Alsina, Merce⁹ (AUTHOR), Vidal, David¹⁰ (AUTHOR), Belinchón Romero, Isabel¹¹ (AUTHOR), Notario, Jaime¹² (AUTHOR), Carrascosa, José M.¹³ (AUTHOR), Gonzalez‐Delgado, Víctor¹⁴ (AUTHOR), Mollet, Jordi¹⁵ (AUTHOR), Ribera, Miquel¹⁶ (AUTHOR)

المصدر: International Journal of Dermatology. Dec2024, Vol. 63 Issue 12, p1720-1727. 8p.

مصطلحات موضوعية: *CERTOLIZUMAB pegol, *PSORIATIC arthritis, *DRUG efficacy, *PATIENT safety, *SURVIVAL rate

المؤلفون: Smolen, Josef S¹ josef.smolen@meduniwien.ac.at, Taylor, Peter C², Tanaka, Yoshiya³, Takeuchi, Tsutomu^4,5, Hashimoto, Motomu⁶, Cara, Carlos⁷, Lauwerys, Bernard⁸, Tilt, Nicola⁹, Ufuktepe, Baran¹⁰, Xavier, Ricardo M¹¹, Balsa, Alejandro¹², Curtis, Jeffrey R¹³, Mikuls, Ted R¹⁴, Weinblatt, Michael¹⁵

المصدر: Rheumatology. Nov2024, Vol. 63 Issue 11, p3015-3024. 10p.

مصطلحات موضوعية: *ANTI-inflammatory agents, *CERTOLIZUMAB pegol, *DATA analysis, *PATIENT safety, *RESEARCH funding, *RHEUMATOID arthritis, *AUTOANTIBODIES, *STATISTICAL sampling, *BLIND experiment, *RANDOMIZED controlled trials, *DESCRIPTIVE statistics, *DRUG monitoring, *ADALIMUMAB, *DRUG efficacy, *STATISTICS, *COMPARATIVE studies

المؤلفون: Kameda, Hideto¹, Nishida, Keiichiro², Nanki, Toshihiro³, Watanabe, Akira⁴, Oshima, Yukiya⁵ yukiya.oshima@ucb.com, Momohara, Shigeki⁶

المصدر: Modern Rheumatology. Nov2024, Vol. 34 Issue 6, p1103-1114. 12p.

مصطلحات موضوعية: *CERTOLIZUMAB pegol, *DRUG side effects, *BLOOD sedimentation, *JAPANESE people, *RHEUMATOID arthritis

المؤلفون: Menshykau, Denis¹ (AUTHOR) denis.menshykau@ucb.com, Sidhu, Jagdev² (AUTHOR), Shaughnessy, Laura³ (AUTHOR), Lledo‐Garcia, Rocio⁴ (AUTHOR), Dua, Pinky⁴ (AUTHOR), Teil, Marie⁵ (AUTHOR), Khandelwal, Akash¹ (AUTHOR)

المصدر: CPT: Pharmacometrics & Systems Pharmacology. Nov2024, Vol. 13 Issue 11, p1904-1914. 11p.

مصطلحات موضوعية: *CERTOLIZUMAB pegol, *TUMOR necrosis factors, *PREGNANT women, *STRUCTURAL models, *CONFIDENCE intervals

المؤلفون: Ting, Magdalene Yin Lin¹ (AUTHOR), Vega-Tapia, Fabian² (AUTHOR), Anguita, Rodrigo^1,2,3 (AUTHOR), Cuitino, Loreto^2,4 (AUTHOR), Valenzuela, Rodrigo A.^5,6 (AUTHOR), Salgado, Felipe² (AUTHOR), Valenzuela, Omar⁷ (AUTHOR), Ibañez, Sebastian⁷ (AUTHOR), Marchant, Ruben⁷ (AUTHOR), Urzua, Cristhian A.^2,7 (AUTHOR) cristhian.urzua@uchile.cl

المصدر: Ocular Immunology & Inflammation. Oct2024, Vol. 32 Issue 8, p1819-1831. 13p.

مصطلحات موضوعية: *CERTOLIZUMAB pegol, *EYE inflammation, *PREGNANCY outcomes, *MATERNALLY acquired immunity, *ALKYLATING agents

المؤلفون: Korge, Bernhard¹ (AUTHOR) hautarzt@dr-korge.de, Vanhooteghem, Olivier² (AUTHOR), Lynde, Charles W.^3,4,5 (AUTHOR), Machovcova, Alena⁶ (AUTHOR), Perrussel, Marc⁷ (AUTHOR), Lazaridou, Elisavet⁸ (AUTHOR), Marasca, Claudio⁹ (AUTHOR), Sarro, David Vidal¹⁰ (AUTHOR), Pousa, Ines Duenas¹¹ (AUTHOR), Fierens, Frederik¹² (AUTHOR), Williams, Paulette¹³ (AUTHOR), Shimizu, Saori¹² (AUTHOR), Heidbrede, Tanja¹⁴ (AUTHOR), Warren, Richard B.^15,16 (AUTHOR)

المصدر: Dermatology & Therapy. Oct2024, Vol. 14 Issue 10, p2923-2926. 4p.

مصطلحات موضوعية: *CERTOLIZUMAB pegol, *TUMOR necrosis factors, *BODY mass index, *BIOTHERAPY, *CHAR

المؤلفون: Takami, Kenji¹ k.takami14@gmail.com, Tsuji, Shigeyoshi², Sato, Sachina³, Akaji, Kazuya³, Yamashita, Chigusa³, Hiroumi, Shiori⁴, Konaka, Hachiro⁴, Hayashi, Misa³, Higashiyama, Mari³

المصدر: Modern Rheumatology. Sep2024, Vol. 34 Issue 5, p1013-1018. 6p.

مصطلحات موضوعية: *CERTOLIZUMAB pegol, *PSORIATIC arthritis, *FACTOR analysis, *ADALIMUMAB, *BIOLOGICALS

المصدر: Multicenter, Open Label or Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis

Other URLs: http://www.Vivli.org

المصدر: A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of Concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis Despite Prior Treatment With Advanced Therapies (bDMARD or tsDMARD)

Other URLs: https://www.janssen.com/clinical-trials/transparency

المؤلفون: Hospital for Special Surgery, New York, University of Toronto, NYU Langone Health

المساهمون: David Ware Branch, MD

المصدر: Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy)
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.
Committee on Practice Bulletins-Obstetrics, American College of Obstetricians and Gynecologists. Practice Bulletin No. 132: Antiphospholipid syndrome. Obstet Gynecol. 2012 Dec;120(6):1514-21. doi: 10.1097/01.AOG.0000423816.39542.0f.
Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1869-73. doi: 10.1002/acr.22066.
Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010 Oct 30;376(9751):1498-509. doi: 10.1016/S0140-6736(10)60709-X. Epub 2010 Sep 6.
de Jesus GR, Agmon-Levin N, Andrade CA, Andreoli L, Chighizola CB, Porter TF, Salmon J, Silver RM, Tincani A, Branch DW. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev. 2014 Aug;13(8):795-813. doi: 10.1016/j.autrev.2014.02.003. Epub 2014 Mar 17.
Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003 Dec;112(11):1644-54. doi: 10.1172/JCI18817. Erratum In: J Clin Invest. 2004 Feb;113(4):646.
Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol. 2007 Feb;196(2):167.e1-5. doi: 10.1016/j.ajog.2006.10.879.
Stone S, Pijnenborg R, Vercruysse L, Poston R, Khamashta MA, Hunt BJ, Poston L. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta. 2006 Apr-May;27(4-5):457-67. doi: 10.1016/j.placenta.2005.04.006. Epub 2005 Jul 6.
Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, Petri M, Porter TF, Sammaritano L, Stephenson MD, Buyon J, Salmon JE. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012 Jul;64(7):2311-8. doi: 10.1002/art.34402.
Gilbert WM, Nesbitt TS, Danielsen B. The cost of prematurity: quantification by gestational age and birth weight. Obstet Gynecol. 2003 Sep;102(3):488-92. doi: 10.1016/s0029-7844(03)00617-3.
Gnanendran L, Bajuk B, Oei J, Lui K, Abdel-Latif ME; NICUS Network. Neurodevelopmental outcomes of preterm singletons, twins and higher-order gestations: a population-based cohort study. Arch Dis Child Fetal Neonatal Ed. 2015 Mar;100(2):F106-14. doi: 10.1136/archdischild-2013-305677. Epub 2014 Oct 30.
Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006 Sep-Oct;27(9-10):939-58. doi: 10.1016/j.placenta.2005.12.006. Epub 2006 Feb 20.
Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010 Jun;63(6):534-43. doi: 10.1111/j.1600-0897.2010.00831.x. Epub 2010 Mar 23.
Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol. 2005 Jan 1;174(1):485-90. doi: 10.4049/jimmunol.174.1.485.
Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, Girardi G. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood. 2007 Oct 1;110(7):2423-31. doi: 10.1182/blood-2007-01-070631. Epub 2007 May 29.
Qing X, Redecha PB, Burmeister MA, Tomlinson S, D'Agati VD, Davisson RL, Salmon JE. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2011 Feb;79(3):331-9. doi: 10.1038/ki.2010.393. Epub 2010 Oct 13.
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003 Mar;111(5):649-58. doi: 10.1172/JCI17189.
Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet. 1983 Jun 18;1(8338):1361-3. doi: 10.1016/s0140-6736(83)92141-4.
Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med. 1985 Nov 21;313(21):1322-6. doi: 10.1056/NEJM198511213132104.
Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992 May;166(5):1318-23. doi: 10.1016/0002-9378(92)91596-3.
Yelnik CM, Laskin CA, Porter TF, Branch DW, Buyon JP, Guerra MM, Lockshin MD, Petri M, Merrill JT, Sammaritano LR, Kim MY, Salmon JE. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med. 2016 Jan 12;3(1):e000131. doi: 10.1136/lupus-2015-000131. eCollection 2016.
Clark CA, Laskin CA, Spitzer KA. Anticardiolipin antibodies and recurrent early pregnancy loss: a century of equivocal evidence. Hum Reprod Update. 2012 Sep-Oct;18(5):474-84. doi: 10.1093/humupd/dms020. Epub 2012 Jun 13.

المؤلفون: Tskhvarashvili, G.¹ (AUTHOR), Aher, K.² (AUTHOR), Sveide, I.² (AUTHOR), Katus, U.¹ (AUTHOR), Westerlund, A.¹ (AUTHOR), Hoti, F.² (AUTHOR), Wennerström, C.³ (AUTHOR), Hassan, F.⁴ (AUTHOR), Lee, J.⁵ (AUTHOR), Hermanrud, C.³ (AUTHOR), Johnsson, I.³ (AUTHOR), Passey, A.³ (AUTHOR), Nissinen, R.⁶ (AUTHOR), Polesie, S.^7,8 (AUTHOR), Mälkönen, T.⁹ (AUTHOR), Saarelainen, L.¹ (AUTHOR) laura.saarelainen@iqvia.com

المصدر: Journal of the European Academy of Dermatology & Venereology. Aug2024, p1. 15p. 4 Illustrations.

مصطلحات موضوعية: *TERMINATION of treatment, *CERTOLIZUMAB pegol, *DRUG therapy, *BIOLOGICALS, *DRUG analysis

المؤلفون: Korge, Bernhard¹ hautarzt@dr-korge.de, Vanhooteghem, Olivier², Lynde, Charles W.^3,4,5, Machovcova, Alena⁶, Perrussel, Marc⁷, Lazaridou, Elisavet⁸, Marasca, Claudio⁹, Sarro, David Vidal¹⁰, Pousa, Ines Duenas¹¹, Fierens, Frederik¹², Williams, Paulette¹³, Shimizu, Saori¹², Heidbrede, Tanja¹⁴, Warren, Richard B.^15,16

المصدر: Dermatology & Therapy. Aug2024, Vol. 14 Issue 8, p2077-2092. 16p.

مصطلحات موضوعية: *CERTOLIZUMAB pegol, *QUALITY of life, *PSORIASIS, *BODY mass index, *PATIENT safety

مصطلحات جغرافية: CANADA

المصدر: Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers

المؤلفون: UCB Japan Co. Ltd.

المصدر: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors
Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Ann Rheum Dis. 2017 Aug;76(8):1348-1356. doi: 10.1136/annrheumdis-2016-210246. Epub 2017 Feb 2.
Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 2016 Jan;75(1):75-83. doi: 10.1136/annrheumdis-2015-207511. Epub 2015 Jul 2.

Other URLs: https://www.clinicaltrials.astellas.com/transparency/

المصدر: Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Arthritis (RA) Who Participated in Open Label Studies C87015, C87028 and C87051